Serum levels of Cholesterol synthesis/absorption markers in subjects of various diseases.
Not Applicable
Recruiting
- Conditions
- ormal subjects, Diabetes, Hyperlipidemia, Essential hypertension, Metabolic syndrome
- Registration Number
- JPRN-UMIN000004946
- Lead Sponsor
- Department of Metabolic Medicine, Faculty of life sciences, Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
1.Subjects with inflammation 2.Subjects with fresh cerebrovascular diseases 3.Subjects with hepatic disorder without fatty liver 4.Subjects with severe respiratory disease or severe heart failure 5.Subjects with alcoholicsm or medicinal intoxication 6.Subjects with psychosis 7.Subjects who doctors judge as unfitness
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1: Calculation of mean value of cholesterol synthesis/absorption markers. 2: Comparison of serum level of cholesterol synthesis/absorption markers between normal subjects and patients with diabetes, hyperlipidemia, hypertension or metabolic syndrome.
- Secondary Outcome Measures
Name Time Method Comparison between cholesterol synthesis/absorption markers and TC, HDL-C, LDL-C, TG, FBG or HbA1.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link cholesterol synthesis markers to metabolic syndrome progression in Kumamoto University's observational study?
How do serum cholesterol absorption markers compare between diabetic patients and normoglycemic controls in JPRN-UMIN000004946?
What biomarkers correlate with treatment response in hyperlipidemia patients with essential hypertension from this trial?
Are there novel therapeutic targets identified through cholesterol metabolism analysis in this multi-disease cohort study?
What adverse events are associated with cholesterol synthesis pathway dysregulation in metabolic syndrome patients observed in this study?